OR WAIT null SECS
In order to combat the threat of counterfeits in Europe, the EU's current anti-counterfeiting directive is being amended.
The full version of this counterfeiting feature can be read in the July issue of our digital magazine: http://www.pharmtech.com/ptedigital0710
With the increasing financial and technical means of counterfeiters, the number of counterfeit pharmaceuticals in the supply chain is growing at an alarming rate. Counterfeiters now have the ability to produce higher quality packages, which enables fake medicines to slip into supply chains more easily.
To combat this threat, the European Parliament and the Council of the EU are amending the current anti-counterfeiting directive (Directive 2001/83/EC), which is due to be completed before the end of 2010, to include a requirement for features that enable the identification, authentication and traceability of prescription medicines. Once this legislation is passed, all European member states will have to implement local legislation within 24 months. Given the legislation's short timeframe, it is imperative that pharmaceutical manufacturers begin to examine and invest in a solution as soon as possible.
The only way a specific product can be identified, authenticated and traced effectively throughout the supply chain is to give it a unique identity. As such, serialisation, which assigns a unique identity via a unique identification number to each product through a vehicle such as RFID or 2D barcode, is the only solution that can comply with the directive.
Examples of authentication and data integrity
Combined, identification, authentication and traceability initiatives make it significantly more difficult for counterfeit drugs to enter the supply chain and reach patients.
Identification allows a specific item to be tracked to the date and batch number that it was manufactured on.
Authentication is the ability to verify that a drug product genuinely came from the manufacturer or other legalised source within the supply chain. To authenticate a product, the pharmacy reads its serialisation code, which when linked to a database, can identify an individual pack and determine that it has not been copied, is in date, has not been recalled and is legally available for sale.
Traceability allows authorised individuals to verify samples of packs to confirm their authenticity before they are distributed, as well as locate and remove the packs from the supply chain if issues are detected. It can also help identify where in the supply chain a counterfeit drug entered.
Identification, authentication and traceability require very high quality serialisation data. If the data are not 100% accurate when the manufacturer applies the serialisation code to a product, then authentication by the pharmacy will be inaccurate. Aside from simply placing a unique number on a package, serialisation technology must also allow a manufacturer to know which numbers have been assigned and placed on which of their products and batches; to be aware of which serialised products are in the supply chain or have been consumed; and to obtain updates regarding the status of specific serialisation numbers in the case of recall, illegal importation or theft.
For serialisation technology to provide such a high quality of data, it must have the ability to maintain control of the product throughout the packaging process. Because such large amounts of data are involved, companies need excellent quality control procedures regarding data integrity; otherwise, for example, there may be problems associated with missing information or overlapping ranges of serialisation numbers. To ensure data integrity is maintained throughout the packaging process, serialisation solutions must:
Because of the emergence of identification, authentication and traceability initiatives, as well as the unpredictability of future serialisation regulations, manufacturers should be examining solutions that can respond to current and new demands quickly and cost effectively. Ideally, the solution should be configurable because such solutions are scalable in that they can manage both small and large throughputs and are also capable of expanding as requirements (e.g., post-lot requirements for serialisation and OEE (Overall Equipment Effectiveness) etc.) are introduced. Configurable serialisation software can be assembled and realigned to quickly accommodate changing demands, allowing it to support a wide variety of packaging line functions and new requirements.
Customised solutions, on the other hand, are very rigid because they are built for one particular need. As such, new code must be written whenever there is a change of equipment on the line or if requirements on the line change. For example, if a manufacturer has been performing serialisation using 2D barcodes and then adds RFID to the line because of new requirements, the customised solution will probably require large changes, such as the writing of new code to manage the new components. Writing new code requires many resources, is very time-consuming and requires the line to be re-validated, thereby shutting down the line.
Configurable solutions do not require new code to be written because they are designed with the necessary elements to address new functions — manufacturers can simply realign and rearrange these elements as required. This eases the need to handle multiple code schemas to comply with different regulations, enables in-house personnel to easily maintain the solution and also speeds implementation. Additionally, revalidation of the line is not required.
The only technology that supports all three of the European Parliament and Council's anti-counterfeiting initiatives is serialisation. However, implementing serialisation throughout the supply chain requires software capable of maintaining a high level of data integrity.
Manufacturers who choose configurable serialisation solutions that maintain the integrity of data throughout the packaging process are best positioned to meet both current and future regulations.
Frederic Menardo is General Manager Europe at Systech International
Graham Smith is Senior VP of Business Development at Aegate